Design Therapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Design Therapeutics, Inc. (DSGN) had Operating Lease, Weighted Average Discount Rate, Percent of 10.70% as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-03
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 10.70%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 10.70%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 10.70% 10-Q · filed 2026-08-03 |
| 2026-03-31 | 10.70% 10-Q · filed 2026-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |